Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater China

Updated : October 13, 2020 10:59 AM IST

Alembic Pharma said Curon obtains the exclusive development and commercialisation rights of Tenalisib for Greater China across all oncology indications.

Alembic Pharmaceuticals, through its wholly-owned subsidiary, holds 50 percent ownership in Rhizen.

Published at Tue, 13 Oct 2020 04:41:15 +0000